Upsher-Smith Laboratories, LLC Selects PANTHERx® Rare for the Distribution of TORPENZ™ (everolimus) Tablets
PITTSBURGH, Aug. 20, 2024 /PRNewswire/ — PANTHERx® Rare, a leader in rare disease product patient access and support...
Read More
PANTHERx® Rare Partnering with Gilead Sciences, Inc. for the Distribution of LIVDELZI®
PITTSBURGH, Aug. 16, 2024 /PRNewswire/ — PANTHERx® Rare, a leader in rare disease product patient access and support...
Read More
PANTHERx®Rare Partnering with ITF Therapeutics LLC for U.S. Distribution of DUVYZAT™
PITTSBURGH, Pa., July 25, 2024 /PRNewswire/ — PANTHERx® Rare, a leader in rare disease product patient access and support...
Read More
PANTHERx Rare Appoints Bansi Nagji as CEO; Rob Snyder appointed Executive Chair
PANTHERx Rare Appoints Bansi Nagji as CEO; Rob Snyder appointed Executive Chair
PITTSBURGH, July 25, 2024 /PRNewswire/ —...
Read More
PANTHERx® Rare Pharmacy Wins Seventh Patient Choice Award
PITTSBURGH, May 1, 2024 /PRNewswire/ — For a seventh time, PANTHERx Rare has been recognized as the winner of the annual...
Read More
PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome
PITTSBURGH, April 29, 2024 /PRNewswire/ — PANTHERx® Rare, a leader in rare disease product patient access and support...
Read More
